Case Report

Monoclonal Gammopathy with Known Significance in TEMPI Syndrome: Case Report and Minireview of the Literature

Jozsef Harasztdombi*, Andras Kozma, Judit Reichardt, Anita Kiss, Kata Kapocs, Laszlo Pajor, Hajnalka Andrikovics, Gabor Mikala

Central Hospital of Southern Pest, National Institute for Hematology and Infectious Diseases, Department of Hematology and Stem Cell Transplantation, Albert Florian ut 5-7 HU-1097 Budapest, Hungary

*Corresponding author: Jozsef Harasztdombi, Central Hospital of Southern Pest, National Institute for Hematology and Infectious Diseases, Department of Hematology and Stem Cell Transplantation, Albert Florian ut 5-7 HU-1097 Budapest, Hungary

Citation: Harasztdombi J, Kozma A, Reichardt J, Kiss A, Kapocs K, et al. (2022) Monoclonal Gammopathy with Known Significance in TEMPI Syndrome: Case Report and Minireview of the Literature. Ann Case Report 7: 779. DOI: 10.29011/2574-7754.100779

Received Date: 14 February, 2022; Accepted Date: 18 February, 2022; Published Date: 22 February 2022

Abstract

TEMPI (telangiectasias, elevated erythropoietin level, and erythrocytosis, monoclonal gammopathy, perinephric fluid collections and intrapulmonary shunting) syndrome is a rare plasma cell neoplasm with associated paraneoplastic features. We diagnosed a new case with IgG kappa paraproteinaemia and a bone marrow plasma cell ratio not reaching the criteria of smoldering myeloma, but harboring translocation t(11;14). Unfortunately, the patient succumbed to central nervous system thrombosis and bleeding, therefore treatment results could not be reported. This sequence of events prompted a reevaluation of the currently available knowledge of TEMPI syndrome.

Introduction

In most cases, monoclonal gammopathy confers unknown significance, but it is occasionally responsible for distinct clinical symptomatology. It was reported as a key feature of the TEMPI syndrome named after the acronym that stands for telangiectasias, elevated erythropoietin level and erythrocytosis, monoclonal gammopathy, perinephric fluid collections and intrapulmonary shunting. This pentad was the main characteristic of the unsolved index patient [1] and additional 5 cases were identified by extensive literature review and international cooperation [2]. In 2011, TEMPI syndrome was called a “novel multisystem disease”, however, today it is already on the map of the World Health Organization as a member of “plasma cell neoplasms with associated paraneoplastic syndrome” alongside with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy/edema, monoclonal gammopathy, skin changes) [3]. To our best knowledge, our patient represents the 28th case. We hope that our patient description and the review will contribute to a better understanding of this extraordinarily rare disease, a monoclonal gammopathy of clinical significance.

Case Presentation

The 52-year-old woman with a history of well-controlled hypertension was referred to our center with polyglobulia (Hemoglobin: 197 g/l, Hematocrit: 58%). This condition was already discovered ten years earlier, but after a therapeutic phlebotomy and taking a single box of hydroxyurea, the patient did not turn up for further evaluation. When she finally returned years later to our institute, itching provoked by hot water was her only symptom, no shortness of breath or flank pain were reported. She was phlebotomized, and her evaluation in the direction of polycythemia vera was started. The non-smoker woman who did not live at a high altitude above sea level surprisingly exhibited a significantly elevated erythropoietin level (EPO: 165.8 mIU/ml, normal range: 3.3–16.6 mIU/ml). Polycythemia vera was ruled out, together with the negative results of the Janus kinase 2 (JAK2) V617F mutation and the wild type sequence of JAK2 exon 12. A monoclonal IgG kappa peak of 7.6 g/l was detected by serum protein electrophoresis and immunofixation. CT scan at this time did not show any possibly EPO producing neoplastic process or...
renal artery stenosis. A 30 mm “cyst” was noticed on the upper pole of the right kidney. The research after the unusual triad of polycytemia, higher EPO level and monoclonal gammopathy led to the suspicion of TEMPI syndrome. This highlighted the significance of the patient’s telangiectasias (Figure 1A), as the possible cutaneous manifestation of this syndrome. Bone marrow histology showed normocellular parenchyma and normal hematopoietic maturation with erythroid dominance (Figure 1C) and 5-10% of plasma cells of combined CD38+/CD56+ phenotype with a kappa light chain dominance (Figure 1D-E). The fluorescence in situ hybridization carried out after CD138 selection of plasma cells showed fusion of IGH-CCND1 signals as a result of a translocation t(11;14)(q13;q32). The 3-month control of the CT scan showed bilateral perinephric fluid collections (Figure 1B). Control EPO levels continued to increase to >500 mIU/ml. These results provided further support for the diagnosis of TEMPI syndrome.

Figure 1: (A) Diffuse telangiectasias visible on the skin of the dorsal trunk. (B) CT scan revealing bilateral perinephric fluid collections. (C) Bone marrow histology: normocellular parenchyma and normal hematopoietic maturation with erythroid dominance, HE, 20x. (D) CD38 immunostaining showing patchy plasma cell infiltration, 20x. (E) kappa light chain immunostaining showing light-chain restriction of plasma cells, 20x.

The patient was immunized with 2 cycles of the SARS-CoV2 mRNA vaccine (Co-mirnaty®). To control the erythrocytosis and the perirenal fluid collection, and to prevent the possible further complications, initiation of a bortezomib-dexamethasone-cyclophosphamide (VCD) treatment regime was chosen and an autologous stem cell transplantation was also planned. One cycle of VCD was completed with a decrease in M-protein production (hematologic response not evaluable). Unfortunately, at her workplace, the patient developed sudden neurological symptoms (vertigo, dysarthria, right-sided hemiplegia with vomiting, and hypertension) with the background of left frontal and left cerebellar ischemia detected by MR angiography. Due to rapid impairment of consciousness, a control CT scan was performed which showed an acute bleeding component in the left frontal lesion. Despite intensive therapy, aggressive dehydration, and decompressive craniotomy, the patient’s condition showed no improvement. MR angiography revealed a subacute thrombosis in the superior sagittal and left transverse sinuses. Reevaluation of the first MRI pictures revealed the signs of sinus thrombosis already present then. The condition of the patient unfortunately deteriorated and she died after 10 years of possible and 1 year of proven history of the TEMPI syndrome.

Discussion

Polyglobulia/erythrocytosis is frequently a presenting symptom and is one of the diagnostic criteria of TEMPI syndrome [4]. Prolonged histories of erythrocytosis treated by phlebotomies or hydroxyurea may occur with no effect on disease progression.
Erythrocytosis secondary to EPO overproduction is a well-known phenomenon, but it does not seem to be the primary motivator of this disease. Aspiration of the perinephric fluid collection [5], marsupialization [6] or decortication [7] of the affected kidney usually does not influence the other disease parameters either. Again, this supports the hypothesis that kidney involvement is not the primary causative factor of TEMPI. Interestingly, monoclonal gammopathy is kappa restricted in most TEMPI cases, whereas M-proteins are nearly exclusively of the lambda class in POEMS syndrome. The only effective treatments for TEMPI are based on targeting the underlying plasma cell population, which supports its central pathogenetic role. It is likely that some soluble factors secreted by the clonal plasma cells or their microenvironment are responsible for the diffuse symptomatology of TEMPI. In fact, a recent report drew attention to MIF (macrophage migration inhibitory factor), with its gene located on chromosome 22q11.23 [8]. This would be analogous to the role of VEGF in POEMS syndrome. To detect a possible amplification of the MIF1 gene, FISH testing with a MIF-specific probe was carried out, however, we found no gross aberration with thorough testing of 300 nuclei. Translocation t(11;14) detected in our case does not seem to be commonly occurring in this setting, although t(11;14) is known to be enriched in rare plasma cell disorders. Therefore, we consider the founding aberration of TEMPI remaining still undetermined, t(11;14) alone does not cause the TEMPI syndrome.

Bortezomib alone [9] or in combination, autologous stem cell transplantation [10], and dexamethasone combined with lenalidomide [11] or even daratumumab [12] were successfully used to treat TEMPI, with clinical regression of telangiectasias, renal symptoms, and erythrocytosis as well. The significance of the underlining plasma cell disorder presenting with monoclonal gammopathy seems to be inarguable, but its role in the pathogenesis is yet to be explored. Increased thromboembolic risk of MGUS is well known [13], although in TEMPI syndrome it is not well defined. Among the first case series published by Sykes et al [2], 3 patients were reported to have a thrombotic event and 2 of them had intracranial bleeding. No further thromboembolic events were reported. Though telangiectasias are commonly observed on the skin surface (mostly on the trunk and the hands), there are indications of similar vascular disorder on the meninges, and at least one case is published where telangiectasias resulted in gastrointestinal bleeding [4]. Bilateral renal fluid collections, telangiectasias, and intrapulmonary shunting were reported as possible results of polycythemia vera that harbors V617F mutation and without any sign of monoclonal gammopathy or EPO overproduction. This observation contests that EPO would have a triggering role behind the vascular features of TEMPI. In the context of monoclonal gammopathy, the detected t(11;14) translocation is unique (Table 1). The bone marrow findings described above for our case are consistent with the literature [14]. The association of IGH-CCND1 rearranged smoldering myeloma and polycythemia were described but lacked other features of the syndrome such as kidney, skin, and pulmonary symptoms [15].

| Author            | Telangiectasia | Erythrocytosis | EPO   | M protein | perinephric fluid | pulmonary shunt | plasma cells | cytogenetics |
|-------------------|----------------|----------------|-------|-----------|-------------------|-----------------|--------------|--------------|
| Bazari et al [1]  | yes            | yes            | >5000 mIU/ml | IgGκ      | yes               | yes             | 5%           | N.R.         |
| Sykes et al [2]   | yes            | yes            | >5000 mIU/ml | IgGκ      | yes               | yes             | >10%         | N.R.         |
| Burton et al [16] | N.R.           | yes            | >5000 mIU/ml | IgGκ      | yes               | yes             | >10%         | N.R.         |
| Olerud et al [17] | yes            | yes            | increased | IgG       | N.R.              | yes             | N.R.         | N.R.         |
| Shaheen et al [18]| N.R.           | yes            | 38 mIU/ml   | N.R.      | yes               | N.R.            | N.R.         | N.R.         |
| Schroyens et al [19]| yes          | yes            | >8000 mIU/ml | IgGκ      | N.R.              | yes             | N.R.         | N.R.         |
| Mohammadi et al [7]| yes          | yes            | 134 mIU/ml  | IgAα      | yes               | no              | 10%          | N.R.         |
| Kwok et al [9]    | yes            | yes            | 100 mIU/ml  | IgGλ      | yes               | N.R.            | 10-15%       | N.R.         |
| Viglietti et al [20]| no            | yes            | 78 mIU/ml   | IgAα      | yes               | N.R.            | N.R.         | N.R.         |
| Ryden et al [21]  | yes            | yes            | 433 mIU/ml  | IgGκ      | yes               | yes             | <10%         | N.R.         |
| Pascart et al [22]| yes            | yes            | >5000 mIU/ml| IgGκ      | no                | yes             | 10.5%        | N.R.         |
Kenderian et al [10] yes yes 8144 mIU/ml IgGκ yes yes 5-10% N.R.
Belizaire et al [23] yes yes 5000 mIU/ml IgGκ yes yes N.R. N.R.
Hutchison et al [24] no yes 32,4 mIU/ml IgGκ renal cyst no 9-15% +5p, +9, +15
Katerji et al [15] no yes 687 mIU/ml IgDλ no N.R. 16% t(11;14)
Debbaneh et al [25] yes N.R. N.R. N.R. N.R. N.R. N.R.
Liang et al [11] N.R. yes 142 mIU/ml IgAκ yes N.R. >10% N.R.
Maquet et al [26] yes yes 525 mIU/ml IgGκ no no 0,4% -13, -X, +1q, -6q
Shizuku et al [27] yes yes 4468 mIU/ml IgGκ yes no 3,1% N.R.
Lor et al [28] yes yes NR IgGκ yes yes 2,5% N.R.
Diral et al [29] yes yes 5428 mIU/ml IgGκ yes yes 20% N.R.
Sun et al [8] yes yes 106 mIU/ml IgGκ yes yes 7% N.R.
yes yes 676,16 mIU/ml IgAκ yes yes 3% N.R.
yes yes 741 mIU/ml IgGκ yes yes 2,5% N.R.
Ruan et al [16] yes yes >750 mUI/ml IgAλ yes yes <10% N.R.
Strobl et al [30] yes yes 537 mIU/ml IgGκ no no 10% N.R.
Harasztdombi et al yes yes 165,8 mIU/ml IgGκ yes N.R. 5-10% t(11;14)

Table 1: Selected features of the cases available in the literature.

Our patient presented typical features of the TEMPI syndrome. Diffuse telangiectasias [16], erythrocytosis and elevated EPO, monoclonal gammopathy, and perinephric fluids are consistent with the previously described cases. Our case described along with others increases the awareness of TEMPI syndrome and raises questions concerning the possible increased risk of thrombosis and central nervous system bleeding associated with TEMPI syndrome.

References
1. Bazari H, Attar EC, Douglas M, Dahl DM, Uppot RN, et al. (2010) Case 23-2010: A 49-Year-Old Man with Erythrocytosis, Perinephric Fluid Collections, and Renal Failure. N Engl J Med. 363: 463-475.
2. Sykes DB, Schroyens W, O’Connell C. (2011) The TEMPI Syndrome-A Novel Multisystem Disease. N Engl J Med. 365: 475-477.
3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th ed. Lyon, France: International Agency for Research on Cancer: 257-258.
4. Sykes DB, O’Connell C, Schroyens W. (2020) The TEMPI syndrome. Blood 135: 1199-1203.
5. Jasim S, Mahmud G, Bastani B, Fesler M. (2014) Subcutaneous bortezomib for treatment of TEMPI syndrome. Clin Lymphoma Myeloma Leuk. 14: e221-30.
6. Shaheen M, Hilgarth KA, Hawes D, Badve S, Antony AC. (2003) A Mexican man with “too much blood.” Lancet 362: 806.
7. Mohammadi F, Wolverson MK, Bastani B. (2012) A new case of TEMPI syndrome. Clin Kidney J. 5: 556-558.
8. Sun C, Xu J, Zhang B, Huang H, Chen L, et al. (2021) Whole-genome sequencing suggests a role of MIF in the patophysiology of TEMPI syndrome Blood Adv. 5: 2563-2568.
9. Kwok M, Korde N, Landgren O. (2012) Bortezomib to treat the TEMPI syndrome. N Engl J Med. 366: 1843-1845.
10. Kenderian SS, Rosado FG, Sykes DB, Hoyer JD, Lacy MQ. (2015) Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation. Blood 135: 2414-2416.
11. Liang S-H, Yeh S-P. (2019) Relapsed multiple myeloma as TEMPI syndrome with good response to salvage lenalidomide and dexamethasone. Ann Hematol. 365: 475.
12. Sykes DB, Schroyens W. (2018) Complete responses in the TEMPI syndrome after treatment with daratumumab. N Eng J Med. 378: 23.
13. Glavey SV, Leung N. (2016) Monoclonal gammopathy: The good, the bad and the ugly. Blood Rev. 30: 223-231.
14. Rosado FG, Oliveira JL, Sohani AR, Schroyens W, Sykes DB, et al. (2015) Bone marrow findings of the newly described TEMPI syndrome: when erythrocytosis and plasma cell dyscrasia coexist. Mod Pathol. 28: 367-372.
15. Katerji R, Hudson CA. (2018) Concurrent Polycythemia of Undetermined Etiology and Smouldering Plasma Cell Myeloma. Case Rep Pathol. 2018: 8761721.

16. Burton IE, Sambrook P, McWilliam LJ. (1994) Secondary polycythaemia associated with bilateral lymphocele. Postgrad Med J. 70: 515-517.

17. Olerud JE, Robertson HT, Hossack KF, Nelp WB, Oldland GF, et al. (1981) A patient with polycythaemia. West J Med. 135: 375-382.

18. Ruan Y; Zhao X, Pan M. (2021) Diffuse telangiectasia: A clue to the TEMPI syndrome. JAAD Case Reports. 10: 99-101.

19. Schroyens WA, O’Connell CL, Lacy MQ, Attar EC, Raje N, et al. (2012) TEMPI: a reversible syndrome following treatment with bortezomib. Blood. 120: 986.

20. Viglietti D, Sverzut J-M, Peraldi M-N. (2012) Perirenal fluid collections and monoclonal gammopathy. Nephrol Dial Transplant. 27: 448-449.

21. Ryden A, Wei K, Roberto R, Thomas M. (2013) Too much blood: a case of the newly described TEMPI syndrome. Chest. 144: 927A.

22. Pascart T, Herbaux C, Lemaire A, Soncin F, Hachulla E, et al. (2016) Coexistence of rheumatoid arthritis and TEMPI syndrome: new insight in microangiogenic-related diseases. Joint Bone Spine. 83: 587-588.

23. Belizaire R, Sykes DB, Chen Y-BA, Spitzer TR, Makar RS. (2015) Difficulties in hematopoietic progenitor cell collection from a patient with TEMPI syndrome and severe iatrogenic iron deficiency. Transfusion. 55: 2142-2148.

24. Hutchinson EJ, Taverna JA, Yu Q, Yeager AM. (2016) Polycythemia: an unusual presentation of multiple myeloma. BMJ Case Rep. 2016: bcr2016216686.

25. Debbaneh M, Permanente K, Chong K. (2018) A case of atrophie blanche in a patient with TEMPI syndrome. J Am Acad Dermatol. 79: S1 AB5.

26. Maquet J, Pericaud K, Mouli G, Bories E, Beck C, et al. (2019) Le TEMPI syndrome, cause exceptionnelle de polyglobulie associee a une gammopathie monoclonale. Rev Med Interne. 40: S2 A105-A214.

27. Shizuku T, Matsui K, Yagi S, Iwabuchi S. (2020) The First Case of TEMPI Syndrome in Japan. Intern Med. 59: 1741-1744.

28. Lor M, Cheng M, Liang B, Cheng CE. (2020) TEMPI syndrome with progressive telangiectasias associated with pulmonary deterioration. JAMA Dermatol. 156: 1379-1380.

29. Diral E, Parma M, Renso R, Pezzatti S, Terruzzi E, et al. (2020) A fatal case of TEMPI syndrome, refractory to proteasome inhibitors and autologous stem cell trans-plantation. Leukemia Research. 97: 106441.

30. Strobl J, Sinz C, Heil PM, Stary G, Weninger W. (2021) Cutaneous ulceration as primary presentation of TEMPI syndrome. J Eur Acad Dermatol Venerol. 35: e891-e894.